Loading clinical trials...

POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy) | Clinical Trials | Clareo Health

TERMINATEDNA

POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)

A Prospective Multicenter Study of Transbronchial Microwave Ablation Using Robotic-Assisted Bronchoscopy in Subjects With Oligometastatic Tumors in the Lung

NCT05299606•Ethicon, Inc.

View on ClinicalTrials.gov

Summary

This is a prospective, multicenter, single-arm study on transbronchial microwave ablation using the NEUWAVE FLEX Microwave Ablation System and Accessories on oligometastatic tumors in the peripheral lung, guided by the Auris MONARCH Platform for visualization and access while using cone beam CT (computed tomography) to confirm probe tip placement and final ablation zone. The primary endpoint is Technique Efficacy, assessed 30-days post-ablation via CT imaging.

Eligibility

Age

22 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Signed informed consent.
•Subjects greater or equal to 22 years old.
•Performance status 0-2 (Eastern Cooperative Oncology Group classification (ECOG).
•Willing to fulfill all follow-up visit requirements.
•Subjects with at least one oligometastatic lung tumor where the primary tumor is controlled (in the opinion of the investigator or treating oncologist).
•Oligometastatic lung tumor(s) planned to be ablated in the outer two-thirds of the lung and not closer than 1cm to the pleura.

Exclusion Criteria

•Pregnant or breastfeeding.
•Subjects with thoracic implantable devices, including pacemakers or other electronic implants.
•Chronic, continuous ventilator support, which uses bi-level positive airway pressure (PAP) to improve lung function for severe conditions. (However, intermittent PAP, for non-pulmonary conditions, such as sleep apnea, is permitted).
•Prior pneumonectomy.
•Severe bronchiectasis (with FEV1 \<30%) or disease deemed to be too severe in the opinion of the investigator.
•Platelet count ≤ 50,000/mm3.
•Subjects with uncorrectable coagulopathy at time of screening.
•Subjects medically unable to stop anti-platelet agents (e.g., aspirin, clopidogrel, prasugrel, ticagrelor) at least 5 days prior to the procedure through 48-72 hours after the procedure.
•Subjects medically unable to stop warfarin at least 3-5 days prior to the ablation procedure, or until INR \< 1.5, through 48-72 hours after the procedure. On the day of the procedure, subjects with an INR \> 1.5 cannot have the procedure completed that day but may be rescheduled or postponed.
•Subjects medically unable to stop anticoagulants (e.g., rivaroxaban, apixaban, dabigatran, endoxaban) at least 3 days prior to the ablation procedure through 48-72 hours after the procedure.
+6 more criteria

Locations (10)

Stanford University School of Medicine

Stanford, California, United States

UCONN Health

Farmington, Connecticut, United States

Minnesota Lung Center

Minneapolis, Minnesota, United States

FirstHealth Moore Regional Hospital

Pinehurst, North Carolina, United States

Cleveland Clinic

Cleveland, Ohio, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

MD Anderson

Houston, Texas, United States

University of Toronto

Toronto, Ontario, Canada

Centre Hospitalier de l'Universite de Montreal

Montreal, Quebec, Canada

Prince of Wales Hospital

Shatin, Hong Kong

Key Dates

Start Date

October 21, 2022

Primary Completion Date

October 18, 2024

Completion Date

October 18, 2024

Last Updated

November 24, 2025

Enrollment

ACTUAL participants

Conditions

Lung Neoplasms

Interventions

Transbronchial Microwave Ablation

DEVICE

LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada

NCT07143110

Lung Neoplasms

View study

RECRUITINGPHASE1

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

NCT06885697

MesotheliomaNeoplasms+6 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 24, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)

Inclusion Criteria

Exclusion Criteria

LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54

Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM

Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques

Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC